Oncology Central

NICE recommends new first-line treatment Lenvima against advanced liver cancer

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal document (FAD) recommending the use of Lenvima® (lenvatinib) on the National Health Service (NHS) in England and Wales as an option for untreated, advanced liver cancer. This represents the first new, first line treatment for advanced liver cancer in a decade. 
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.